

## Supplementary Materials

### **A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells Without Mediating Fratricide**


+Ge Yang<sup>1</sup>, +Shahryar Khoshtinat Nikkhoi<sup>1</sup>, Hajar Owji<sup>1</sup>, Geng Li<sup>1</sup>, Mohammad Massumi<sup>1</sup>, Jessica Cervelli<sup>2</sup>, Venu Gopal Vandavasi<sup>3</sup>, and \*Arash Hatefi<sup>1,4</sup>

<sup>1</sup>Department of Pharmaceutics, Rutgers University, Piscataway, NJ 08854, USA


<sup>2</sup>Environmental and Occupational Health Science Institute, Flow Cytometry Core Facility, Rutgers University, Piscataway NJ 08854, USA

<sup>3</sup>Department of Chemistry, Biophysics Core Facility, Princeton University, Princeton, NJ, 08544, USA


<sup>4</sup>Cancer Pharmacology Program, Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA



**Figure S1:** ADCC assay using NK92 as effector cells and SKOV-3 as target cells at E:T ratio of 4. BiKE-E5:C1 and trastuzumab (Trz) were used at 10 nM concentration. n.s.: not significant, t-test,  $p > 0.05$ .



**Figure S2:** Fratricide assay using daratumumab alone or in combination with 3G8 or Fc blocker at different concentrations (24 h incubation time).



**Figure S3:** Flow cytometry data for degranulation of laNK92 cells after incubation with antibodies.